SCHEMBL26075148

SCHEMBL26075148

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 6/20 0.43
▸ KDM4E B2RXH2 5/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ SCN9A Q15858 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ DHODH Q02127 3/20 0.42
▸ PLA2G2A P14555 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ GRM5 P41594 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ TP53 P04637 2/20 0.39
▸ USP2 O75604 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075130 0.92 HMOX1 (0.43) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075173 0.91 SCN9A (0.42) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075168 0.90 PDE10A (0.46) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075150 0.89 MEN1 (0.46) PDE10ASMN1; SMN2HPGDSCN9ADHODH
SCHEMBL26075154 0.89 KDM4E (0.50) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075988 0.88 PDE10A (0.45) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075298 0.88 HMOX1 (0.45) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL23579974 0.87 DHODH (0.59) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL29996463 0.87 DHODH (0.59) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL26075139 0.84 PDE10A (0.42) PDE10AKDM4EALDH1A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PDE10A 3462/4885KDM4E 1396/4885ALDH1A1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback